Importantly, loss‐of‐function mutations in CDKN2A, and its binding partner, the product of the cyclin‐dependent kinase 4 (CDK4) gene, have been identified in highly melanoma‐prone families 8, 9, 10, firmly linking disruption of cell cycle control and melanoma risk. Here, CDKN2A is linked to melanoma.